Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

GW873140 In Combination With Combivir In HIV Infected Subjects

ClinicalTrials.gov ID: NCT00104429

Public ClinicalTrials.gov record NCT00104429. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PhaseIIb, 96 Week, Randomised, Partially Double-blinded, Multicentre, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of GW873140 in Combination With COMBIVIR (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults

Study identification

NCT ID
NCT00104429
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
ViiV Healthcare
Industry
Enrollment
125 participants

Conditions and interventions

Interventions

  • GW873140 Drug
  • Combivir Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2004
Primary completion
Dec 31, 2005
Completion
Dec 31, 2005
Last update posted
May 29, 2017

2005 – 2006

United States locations

U.S. sites
27
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
GSK Investigational Site Bakersfield California 93301
GSK Investigational Site Beverly Hills California 90210
GSK Investigational Site Los Angeles California 90022
GSK Investigational Site Los Angeles California 90095
GSK Investigational Site San Francisco California 94114
GSK Investigational Site Stanford California 94305
GSK Investigational Site Tarzana California 30342
GSK Investigational Site Denver Colorado 80205
GSK Investigational Site Washington D.C. District of Columbia 20009
GSK Investigational Site Miami Florida 33136
GSK Investigational Site Orlando Florida 32804
GSK Investigational Site Tampa Florida 33607
GSK Investigational Site Vero Beach Florida 32960
GSK Investigational Site Conyers Georgia 30013
GSK Investigational Site Chicago Illinois 60612
GSK Investigational Site Boston Massachusetts 02114
GSK Investigational Site Minneapolis Minnesota 55404
GSK Investigational Site Las Vegas Nevada 89102
GSK Investigational Site Newark New Jersey 7102
GSK Investigational Site New York New York 10008
GSK Investigational Site Rochester New York 14604
GSK Investigational Site Portland Oregon 97210
GSK Investigational Site Philadelphia Pennsylvania 19107
GSK Investigational Site Providence Rhode Island 02908
GSK Investigational Site Dallas Texas 75208
GSK Investigational Site Dallas Texas 75215
GSK Investigational Site Dallas Texas 75246

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00104429, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 29, 2017 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00104429 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →